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Abstract
Background: The aim is to assess the validity and reliability of transbronchial needle aspiration (TBNA) of mediastinal 
and hilar adenopathies and to evaluate factors predictive of TBNA outcome.
Methods: We performed an analysis of prospectively collected data of patients (n = 580) who underwent TBNA (n = 
685) from January 1998 to December 2007 in our center. Validity and reliability were evaluated for the overall sample 
and according to specific pathology. Factors predicting the successful acquisition of diagnostic samples were analyzed 
by multivariate analysis.
Results: Overall sensitivity, specificity, accuracy, and positive and negative predictive (NPV) values for TBNA were 68%, 
100%, 68.8%, 100%, and 10%, respectively. The most sensitive and accurate TBNAs were obtained for patients with 
small cell lung carcinoma and the worst results were for patients with lymphomas. NPV were similar for all pathologies. 
The most predictive factors of outcome were adenopathy size and the presence of indirect signs at the puncture site.
Conclusion: The sensitivity and accuracy of TBNA are high in small cell lung cancer, followed by other types of 
carcinoma, sarcoidosis, and tuberculosis, and low for lymphoproliferative diseases. The NPV of TBNA for all individual 
pathologies is low. The size of the adenopathy and the presence of indirect signs at the puncture site predict the 
achievement of diagnostic samples.
Background
Transbronchial needle aspiration (TBNA) is a minimally
invasive bronchoscopic technique that is cost-effective
and safe for diagnosing mediastinal and hilar adenopa-
thies in patients with lung cancer and other pathologies,
including other cancers, sarcoidosis, and infectious pro-
cesses such as tuberculosis [1,2]. However, there is great
variability in the results obtained depending on endosco-
pist experience [3], adenopathy characteristics and their
location [4-6], type of needle used [1,2,7], etiology of
mediastinal adenopathies [8], possibility of an immediate
evaluation by a cytopathologist [9], or use of accessory
techniques such as bronchoscopic ultrasound for ade-
nopathy detection [10]. Further, factors that can influence
the evaluation of the outcome are prevalence of underly-
ing pathologies [11] and interpretation of the results from
other published studies [12,13]. Most of the studies on
the validity and reliability of TBNA as diagnostic tool for
mediastinal and hilar adenopathies have been performed
in patients with lung cancer. Few studies have analyzed
the sensitivity, specificity, predictive values, and TBNA
accuracy for diagnosing diseases that produce frequently
mediastinal adenopathies [8] and those that have small
sample sizes. Therefore, it is difficult to compare the
results among studies and perform a global evaluation of
the technique.
The purpose of this study was to evaluate the validity
and the predicitive value of TBNA for diagnosing medi-
astinal adenopathies of different etiologies in a large
cohort of patients treated at a tertiary care hospital over
10 years and to determine which factors might predict
TBNA outcome.
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Methods
Study Design and Scope
We performed an analysis of prospective collected data of
patients with thoracic computerized tomography (CT)-
detected mediastinal and hilar adenopathies adjacent to
the tracheobronchial tree (with the short axis ≥ 10 mm)
who underwent consecutively TBNA at Xeral Hospital of
Vigo from January 1998 to December 2007. Xeral Hospi-
tal of Vigo is a tertiary care hospital which is part of the
Vigo University Hospitalary Complex and serves 250,000
people. About five hundred bronchoscopies are per-
formed annually. TBNAs were performed by experienced
bronchoscopists and residents under their supervision.
Those patients for whom a final diagnosis could not be
o b t a i n e d  w e r e  e x c l u d e d  f r o m  t h e  s t u d y .  P a r t  o f  t h e s e
patients were included in some previous studies [6,14,15].
TBNA Materials and Methods
Different types of cytology needles [MW-122 (22 gauge;
Bard-Wang, Billerica, USA), NA-401D-1321 and NA-
401D-1321 (21 gauge; Olympus, Tokyo, Japan), and eXce-
lon 21 gauge (Boston Scientific, Boston, USA)] and a
unique model of histology needle [MW-319 (19 gauge;
B a r d - W a n g ,  B i l l e r i c a ,  U S A ) ]  w e r e  u s e d  t o  p e r f o r m
TBNA. Needle type selection depended on availability at
the time of TBNA and on the clinical suspicion of
patient's pathology. Histology needles were used when
the pathology was suspected to be of benign origin or
lymphoproliferative processes; cytology needles were
used in all the other cases.
Patient preparation for TBNA was the same as for all
diagnostic bronchoscopies performed in the hospital.
After the procedure, the patient's personal data, age, sex,
description and location of the lesions detected in tho-
racic CT, endoscopic findings including the presence of
i n d i r e c t  s i g n s  s u c h  a s  h y p e r e m i a ,  e d e m a ,  o r  e x t r i n s i c
compression of the carina or widening at the puncture
point, were recorded on a standardized form. Finally, all
patients were followed until the moment a definitive
diagnosis was made.
Potential risks of the endoscopic techniques were
explained to all patients and all patients provided
informed consent. Patients were pre-medicated with 0.5
mg atropine intramuscularly and underwent conscious
sedation with intravenous midazolam. Bronchoscopy was
performed transnasally using 2% lidocaine as local anes-
thesia with the patient in the supine decubitus position.
TBNA of selected mediastinal or hilar adenopathies sta-
tions was performed before bronchial tree exploration,
avoiding bronchoscopic aspiration or contamination with
secretions, as far as possible. The insertion point was
determined after a careful analysis of thoracic CT and fol-
lowing previous recommendations by other authors [1,2].
When several adenopathies were selected, TBNA was
carried out at the most accessible and largest adenopathy.
We collected a sample from another station only if we
could not obtain at least one adequate sample from the
primary station after three or four attempts. A cyto-
pathologist was present during the procedure and made
an immediate microscopic evaluation of the cytology
samples and a macroscopic evaluation of histology sam-
ples. Cases with a lesion on the tracheobronchial mucosa
at the puncture point were not included in the study.
Data interpretation
All samples with high lymphoid cellularity (at least 30%
[5]) suggesting a lymph node puncture or the existence of
many neoplastic cells or cytological/histological findings
that allowed for a specific diagnosis ("diagnostic sam-
ples") were considered "adequate samples". Samples with
atypias or dubious, mucousy, bloody, or tracheobronchial
wall cellularity were considered "non-adequate".
In all patients with TBNA performed in more than one
lymph node station, the best diagnosis or the most ade-
quate, if there was disagreement, was selected. Every
patient was considered as an analysis unit [16].
All diagnostic samples, those with abundant lymphoid
cellularity confirmed by a surgical technique, and those
with benign pathology that did not change or disappeared
after six months were considered true positives (TP). TPs
were not further confirmed by a surgical technique due to
the very high specificity of TBNA; false positives (FP) are
extremely infrequent. Cases yielding only a very high
lymphoid cellularity in patients with specific pathologies
such as carcinomas, lymphomas, tuberculosis, or sarcoi-
dosis, and whose surgical biopsies produced results simi-
lar to those of TBNA were considered true negatives
(TN). The samples with lymphoid cellularity not con-
firmed by surgical techniques or follow-up and all
patients with non-adequate TBNAs were considered false
negatives (FNs).
The diagnosis of carcinoma or lymphoma was made
according to standard criteria. Sarcoidosis was diagnosed
when sarcoid granulomas were found and other diseases
with similar clinical or radiologic findings could be rea-
sonably excluded. Tuberculosis was diagnosed when the
cytohistologic samples showed necrotizing granulomas
with or without Mycobacterium tuberculosis isolation and
the patient had a good response to antituberculosis treat-
ment. Anthracotic or reactive adenopathies were diag-
nosed according to clinical criteria, occupational
exposure, cytohistologic results (numerous benign lym-
phocytes and resolution of patient process or few lym-
phocytes plus numerous anthracotic pigment-laden
macrophages), and clinical-radiologic follow-up (stabili-
zation or disappearance of the nodes), and were consid-
ered non-specific pathologies.Fernández-Villar et al. BMC Pulmonary Medicine 2010, 10:24
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Statistical analysis
Qualitative variables are reported as absolute frequencies
and percentages and numeric variables are reported as
median and range [median (range)]. Sensitivity, specific-
ity, positive predictive value (PPV), negative predictive
value (NPV) and accuracy were determined using the
standard definitions.
Comparison of discrete variables was performed by Chi
squared or the Fisher exact test. All factors associated
with the acquisition of diagnostic samples with a p-value
< 0.20 in univariate analysis were used in multivariate
analysis; odds ratios (OR) and 95% confidence intervals
(95% CI) were determined. In the logistic regression
model, the quantitative variables were divided in two
groups: lesser than and greater than or equal to the
median, in order to obtain more potent estimations.
Underlying pathologies were classified into two groups:
malignant (carcinomas or lymphomas) and benign (all
other causes). Analyses were performed with SPSS, ver-
sion 15.0 (SPSS, Chicago, IL, USA).
In all cases a signed informed consent form was
obtained. The study protocol was approved by the Ethics
Committee of the Xeral Hospital (Vigo, Spain).
Results
Population description
F ive hundred and eigh ty pa tien ts wer e included in the
study. Six hundred and eighty-five TBNAs were per-
formed in different lymph node stations (479 in one site
only, 97 in two sites, and four in three sites). The age of
the patients was 62.0 (21-89) years, 422 (72.8%) males.
Cytology needles were used in 414 (71.4%) cases and his-
tology needles were used in 166 (28.6%) cases. Patient
characteristics and final diagnoses for all patients are pre-
sented in Table 1.
The smallest axis diameter of the studied adenopathies
was 20.0 (10-85) mm; 274 (47.2%) were smaller than 20
mm. An median of 2.0 (1-6) passes were performed. The
frequencies at which TBNA was performed for specific
nodes were right paratracheals, 320; subcarinals, 238; left
paratracheals, 62; hilars, 30; principal bronchus, 5; pre-
carinals, 28; and retrocarinals, 2. Table 2 shows the char-
acteristics of the adenopathies detected for the sample as
a whole and according to patient illness.
TBNA Validity and Reliability
Adequate samples were obtained for 439 (75.7%) patients.
Cytohistologic diagnoses could be made for 343 (59.1%)
patients and there was abundant lymphoid cellularity in
96 (16.6%) patients. Samples obtained through TBNA
were considered non-adequate for 141 (24.3%) patients.
Of the 237 patients for whom a specific diagnosis could
not be made based on TBNA (141 with inadequate sam-
ples + 96 with only lymphoid cellularity in the samples),
diagnoses were ultimately established for 106 (44.7%): 65
patients were diagnosed using surgical techniques and 41
patients were diagnosed during clinical-radiologic follow-
up.
Table 3 shows the sensitivity, specificity, PPV, NPV and
accuracy for TBNA. Sensitivity and accuracy were lower
for lymphomas than for other pathologies except anthra-
cotic and reactive adenopathies. The NPV was low for
every diagnosis group and there were no significant dif-
ferences among the groups.
The diagnoses of 63 of the patients whose samples had
abundant lymphoid cellularity and could not support a
specific diagnosis were ultimately verified. Of them, 42
were considered TPs (all were anthracotic or reactive
adenopathies), 14 were TNs, and seven were FNs (sensi-
tivity, 85.7%; NPV, 66.7%; accuracy, 88.9%).
Factors Influencing the Acquisition of Diagnostic Samples
In univariate analysis (Table 4), factors associated with
the acquisition of diagnostic samples with p < 0.20 were
type of disease, type of needle used, adenopathy diameter,
and the existence of indirect signs at the insertion site. In
multivariate analysis, only adenopathy diameter and the
existence of indirect signs at the insertion site were inde-
pendent predictors of acquiring a diagnostic sample
(Table 4).
Complications
Complications related to TBNA occurred in 12 patients
(2.1%): 11 cases of mild to moderate, self-limited bleeding
at the puncture site and one case of pneumomediastinum
and subcutaneous emphysema.
Discussion
The majority of primary studies and even some meta-
analyses about the validity and reliability of TBNA in
mediastinal adenopathies have been performed in
patients with a single type of pathology, mainly non-small
cell lung cancer [4-7,11]. Only a few of these studies have
evaluated the effectiveness of TBNA for large samples of
different pathologies [8]; these studies provide us a
broader understanding of the technique's utility.
The validity of a diagnostic tool is the degree to which
the test measures what is intended to be measured and is
normally determined by evaluating its sensitivity and
specificity. The reliability of a diagnostic tool is indicated
by the predictive value of a positive or negative result and
indicates the reliability with which this test predicts the
presence or absence of illness. This probability is influ-
enced by the prevalence of the pathology studied and by
the "gold standard" diagnostic techniques used for com-
parison. The same apply to TBNA, as shown by Holty et
al [11] their meta-analysis.Fernández-Villar et al. BMC Pulmonary Medicine 2010, 10:24
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In general, when TBNA is performed, three different
situations occur: 1) enough sample is obtained to make a
specific cytologic or histologic diagnosis; 2) inadequate
or insufficient sample is obtained; or 3) enough sample is
obtained for cytology or biopsy (abundant lymphoid cel-
lularity) but it is impossible to affirm whether is the sam-
ple is representative of the pathology suspected [17]. In
most studies, samples that provided a specific diagnosis
were considered TPs, given the high PPV ascribed to the
technique [4,5,11,17]. However, there is substantial dis-
agreement about the definitions of FN and TN in the lit-
e r a t u r e ;  i n  s o m e  s t u d i e s ,  o n l y  a d e q u a t e  s a m p l e s  w e r e
included in the analysis [18,19] which resulted in overes-
timation of the validity and reliability of TBNA. In other
studies, non-adequate samples that were verified but did
not have lymphoid cellularity were considered TNs and
not FNs. In still other studies, the definition of FN was
based on the influence that the TBNA result had in the
final decision about patient management [7]. In 15-25%
of TBNAs, a representative sample is obtained but a spe-
cific diagnosis cannot be made [6,17]. For example, if the
patient has a carcinoma, it is possible to find a TN (nor-
mal or reactive node) or a FN (metastatic adenopathy,
although not appearing in cytologic smears or in biopsies
Table 1: Final diagnoses, patient characteristics, needle type used, and cases in which TBNA was the only technique that 
permitted the diagnosis.
Pathology Patients, n (%) Age# in years Male, n (%) Cytology needle, n (%) Unique diagnostic, n (%)
Non-small cell lung 
carcinoma¶
280 (48.3%) 62.0 (42-87) 221 (79.5%) 262 (93.6%) 96 (34.2%)
Small cell lung 
carcinoma
74 (12.8%) 65.0 (34-89) 62 (83.8%) 62 (83.8%) 30 (40.5%)
Extrapulmonary 
carcinoma+
44 (7.6%) 61.5 (26-81) 21 (47.7%) 34 (77.3%) 16 (36.3%)
Sarcoidosis 57 (9.8%) 39.5. (21-75) 29 (58.9%) 4 (7.0%) 20 (35.1%)
Tuberculosis 19 (3.3%) 58.0 (38-79) 11 (57.9%) 3 (15.8%) 8 (42.1%)
Lymphoma 15 (2.6%) 66.0 (29-81) 7 (46.7%) 3 (20.0%) 4 (26.7%)
Anthracotic and 
reactive
91 (15.7%) 63.0 (21-85) 71 (78.0%) 46 (50.5%) 11 (12.1%)
Total 580 62.0 (21-89) 422 (72.8%) 414 (71.4%) 214 (31.8%)
#Data are presented as median (range).
¶130 adenocarcinomas, 83 large-cell undifferentiated carcinomas, 67 squamous cell carcinomas.
+13 breast, 10 renal, 5 larynx, 4 colon, 3 gastric, 2 hepatocarcinoma, 2 prostate, 1 endometrium, 1 ovary, 1 bladder, 1 thymus, 1 esophagus.
Table 2: Characteristics of the mediastinal and hilar adenopathies.
Pathology Lymph nodes 
examined
Lymph nodes per patient# Passes# Lymph node size, mm#
Non-small cell 
lung carcinoma
314 1.0 (1-2) 2.0 (1-5) 19.0 (10-85)
Small cell lung 
carcinoma
78 1.0 (1-2) 2.0 (1-6) 28.5 (10-79)
Extrapulmonary 
carcinoma
55 1.0 (1-3) 2.0 (1-6) 21.0 (10-42)
Sarcoidosis 82 1.0 (1-3) 3.0 (1-4) 20.0 (10-45)
Tuberculosis 27 1.0 (1-2) 3.0 (2-4) 20.0 (10-39)
Lymphoma 20 1.0 (1-2) 3.0 (2-5) 23.0 (10-41)
Anthracotic and 
reactive
109 1.0 (1-3) 3.0 (1-6) 15.0 (10-59)
Total 685 1.0 (1-3) 2.0 (1-6) 20.0 (10-85)
#Data are presented as median (range).Fernández-Villar et al. BMC Pulmonary Medicine 2010, 10:24
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obtained by TBNA). In one recent study, the frequency of
such cases was 24% [17]. In our opinion, when the sample
is inadequate (a few lymphocytes, mucus, blood, bron-
chial wall cells, few atypic cells, or not enough tissue sam-
ple), the sample should be considered a FN because the
cellularity does not represent that of the node. Neverthe-
less, some authors consider that inadequate samples
should not be included when evaluating TBNA validity
and reliability as a diagnostic tool [18,19]. TN designa-
tions should be reserved for patients with specific pathol-
ogies for whom TBNA results were representative of a
lymphatic node puncture and the diagnosis was con-
firmed by other techniques [17,20].
In our study, we found that the validity of TBNA in dif-
ferent pathologies responsible for mediastinal adenopa-
thy varied considerably. The greatest sensitivity and
accuracy were obtained for small cell lung carcinoma and
the least for lymphoproliferative diseases. This could be
due to the higher diameter of adenopathies in patients
w i t h  s m a l l  c e l l  c a r c i n o m a ,  a s  t h i s  t y p e  o f  n e o p l a s i a  i s
aggressive and its cells have poor adhesion qualities
[4,6,8]. The poor results obtained in cases of lymphoma
could reflect the need for larger samples to make a spe-
cific diagnosis of the type of lymphoma [20]. Moreover,
we considered samples that were ambiguous or sugges-
tive but not completely conclusive to be non-adequate.
There were no significant differences in TBNA outcomes
among non small cell lung carcinomas, extrapulmonary
carcinomas, sarcoidosis, and tuberculosis. Anthracotic
and reactive adenopathies presented special situations. In
many of them, the next step was the follow-up, taking
into account the low clinical suspicious of specific pro-
cesses. However, according to a recently published sys-
tematic review [21], these differences are not observed in
most published studies when TBNA is performed with
ultrasound (EBUS-TBNA) and the sensitivity of EBUS-
T BNA is m u c h hi gher  t han t he  r eport ed in t his  s t udy
with convencional TBNA alone.
The low NPV we found for all pathologies (≈ 10%) as
compared to published NPVs [18-20] is particularly nota-
ble because the NPV may influence patient management.
It is possible that the restrictive definitions we used for
FN and TN contributed to this low NPV. A recent retro-
spective study analyzed the results of TBNA of mediasti-
nal adenopathies in 194 patients (157 with lung cancer).
The NPV of TBNA was 29% if all results were included
and 64% if only adequate samples were evaluated [18].
However, results similar to ours (NPV = 11-20%) were
reported in several recent studies using endoscopic ultra-
sound in patients with lung cancer and sarcoidoisis
[10,21-24]. This suggests that any negative test should be
verified by other techniques [19,25], even when only a
large number of lymphocytes are present, because the
NPVs for these cases in our study were less than 70%.
In our study, the factors with the greatest influence on
the acquisition of diagnostic samples were the size of the
adenopathy and the presence of indirect signs at the
puncture point. Other factors such as pathology respon-
sible for the mediastinal adenopahies and type of needle
used were not significant. In a study of 166 patients,
Sharafkhaneh et al. [8] found that the type of illness and
diameter of the node were the most important predictors
of TBNA outcome. The differences between their results
and ours could be due to the fact that Sharafkhaneh's
group obtained lower yields from patients with benign
pathologies than malignant pathologies (37% vs. 69%,
respectively) [8]. Even though we obtained high sensitiv-
ity and accuracy associated with small cell lung carci-
Table 3: Validity, reliability, and pre-test probability of TBNA outcome for diagnosing mediastinal and hilar adenopathies.
Pathology Patients Se Sp PPV NPV*** Accuracy
Non-small cell lung carcinoma* 280 68.3% 100% 100% 9.5% 69.3%
Small cell lung carcinoma** 74 93.2% 100% 100% 16.7% 93.2%
Extrapulmonary carcinoma* 44 69.8% 100% 100% 7.1% 70.5%
Sarcoidosis* 57 63.6% 100% 100% 9.1% 64.9%
Tuberculosis* 19 72.2% 100% 100% 16.7% 73.7%
Lymphoma 15 35.7% 100% 100% 10.0% 40.0%
Anthracotic and reactive 91 52.7% - 100% - 52.7%
Total 580 68.0% 100% 100% 10.0% 68.8%
Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value.
* p of sensitivity and accuracy < 0.05 compared with the lymphoma group.
** p of sensitivity and accuracy < 0.001 compared with all other pathologies.
*** No statistically significant differences between the various pathologies.Fernández-Villar et al. BMC Pulmonary Medicine 2010, 10:24
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noma when all neoplastic processes (except lymphomas)
were considered, the type of illness was not an indepen-
dent predictor of outcome.
In various recent studies, obtaining samples for histol-
ogy and cytology using needles with the capacity to
obtain both types of samples increased the diagnostic
yield for different types of pathologies [7,17,26]; however,
we found that the type of needle used did not influence
the outcome. This might be because we used histology
needles for patients suspected of having benign pathol-
ogy or lymphoproliferative disease. In these cases, cytol-
ogy samples are not routinely processed.
Our study does have some limitations, most of which
are similar to those of other studies concerning the effi-
cacy of TBNA. The most important is the lack of result
verification by a surgical "gold standard" technique
([2,19]. However, in light of the high PPV reported for
TBNA and that we have considered the worst-case sce-
narios by classifying all negative TBNAs that were not
subsequently confirmed as FNs, this limitation might be
less important than in other studies [12]. As well, our
study has some advantages over other similar studies, one
of which is that the study was conducted by the same
team and included a variety of pathologies in a large
cohort of patients obtained using a consecutive sampling
of all patients who underwent during a 10 year follow-up.
Ours represents one of the largest series published to date
and the only one that analyzes TBNA validity and reliabil-
ity as diagnostic tool for differentiating among patholo-
gies that produce mediastinal adenopathies. It should be
highlighted that EBUS was not available in most centers
when our recruitment period started,
Table 4: Univariate and multivariate analysis of factors predicting the acquisition of diagnostic samples for mediastinal 
and hilar adenopathies by TBNA.
Factors Diagnostic samples Univariate analysis Multivariate analysis
p-value OR (95% CI) p-value
Sex
Male 291/422 (69.0%) 0.9 - -
Female 106/154 (68.8%)
Age
< 60 years 191/275 (69.5%) 0.7 - -
≥ 60 years 202/297 (68.0%)
Type of disease
Malignant 297/413 (71.9%) 0.07 1.2 (0.7-2.0) 0.3
Benign 101/167 (60.5%)
Type of needle
Cytology 291/414 (70.3%) 0.1 1.1 (0.7-1.9) 0.4
Histology 107/166 (64.5%)
Lymph node station
Right paratracheal 161/234 (68.8%) 0.3 - -
Subcarinal 106/147 (72.1%)
Left paratracheal 36/50 (72.0%)
Others 34/47 (72.3%)
Combination (2 or 
more)
61/102 (60.0%)
Lymph node size
< 20 mm 159/274 (58.0%) 0.0001 2.2 (1.4-3.2) 0.0001
≥ 20 mm 239/306 (78.1%)
Indirect sign
No 246/391 (62.9%) 0.0001 1.7 (1.1-2.6) 0.02
Yes 152/189 (80.4%)
CI: confidence intervalFernández-Villar et al. BMC Pulmonary Medicine 2010, 10:24
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Conclusion
TBNA is a sensitive and accurate technique for obtaining
diagnostic samples from patients with mediastinal ade-
nopathies, especially small cell lung cancer. The size of
the adenopathy was the most important predictor of the
outcome. For other neoplastic or granulomatous ill-
nesses, although the efficacy of the technique is lower
than that observed for small cell lung cancer, its low cost
and few complications justify the continued use of classi-
cal TBNA as the best initial diagnostic test, especially
when other techniques, such as ultrasound bronchos-
copy, are unavailable. The reliability of TBNA for medi-
astinal adenopathies, as determined by its predictive
values, was similar for all the analyzed pathologies.
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